US20140080764A1 - Drug Containing Recombinant Mistletoe Lectins for Treating Malignant Melanoma - Google Patents
Drug Containing Recombinant Mistletoe Lectins for Treating Malignant Melanoma Download PDFInfo
- Publication number
- US20140080764A1 US20140080764A1 US14/009,961 US201214009961A US2014080764A1 US 20140080764 A1 US20140080764 A1 US 20140080764A1 US 201214009961 A US201214009961 A US 201214009961A US 2014080764 A1 US2014080764 A1 US 2014080764A1
- Authority
- US
- United States
- Prior art keywords
- drug
- mistletoe lectin
- recombinant mistletoe
- malignant melanoma
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 201000001441 melanoma Diseases 0.000 title claims abstract description 35
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 title claims abstract description 27
- 235000014066 European mistletoe Nutrition 0.000 title claims description 59
- 235000012300 Rhipsalis cassutha Nutrition 0.000 title claims description 59
- 241000221012 Viscum Species 0.000 title claims description 59
- 108090001090 Lectins Proteins 0.000 title claims description 55
- 102000004856 Lectins Human genes 0.000 title claims description 55
- 239000002523 lectin Substances 0.000 title claims description 55
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 201000000849 skin cancer Diseases 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 1
- 239000005414 inactive ingredient Substances 0.000 claims 1
- 238000011272 standard treatment Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 description 29
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 19
- 229960003901 dacarbazine Drugs 0.000 description 18
- 206010027476 Metastases Diseases 0.000 description 10
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 10
- 208000021039 metastatic melanoma Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 238000009096 combination chemotherapy Methods 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000011301 standard therapy Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010029098 Neoplasm skin Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960003181 treosulfan Drugs 0.000 description 3
- 229960004355 vindesine Drugs 0.000 description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 102000045222 parkin Human genes 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000221013 Viscum album Species 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 102000043321 human CTLA4 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 108010022050 mistletoe lectin I Proteins 0.000 description 1
- 231100000181 multiple organ toxicity Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009279 non-visceral effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Definitions
- the combination of chemotherapy drugs and cytokines shows partially highly response rates (ORR) in comparison to monotherapies, but the survival time is not improved.
- ORR partially highly response rates
- the combination of IL-2 and cisplatin exhibited a high response rate, of 50%, having a short duration, although this was accompanied by strong side effects (undesired effects).
- a monotherapy with dacarbazine and a combination of dacarbazine, cisplatin, IFN- and IL-2 no differences were observed between the two methods of treatment (Flaherty et al. 2001 (supra), Danson et al. 2003 (supra), Agarwala et al.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11161400.4 | 2011-04-06 | ||
| EP11161400A EP2508195A1 (de) | 2011-04-06 | 2011-04-06 | Arzneimittel enthaltend rekombinante Mistellektine zur Behandlung des malignen Melanoms |
| PCT/EP2012/056479 WO2012136857A1 (de) | 2011-04-06 | 2012-04-10 | Arzneimittel enthaltend rekombinante mistellektine zur behandlung des malignen melanoms |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2012/056479 A-371-Of-International WO2012136857A1 (de) | 2011-04-06 | 2012-04-10 | Arzneimittel enthaltend rekombinante mistellektine zur behandlung des malignen melanoms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/064,371 Division US9981007B2 (en) | 2011-04-06 | 2016-03-08 | Drug containing recombinant mistletoe lectins for treating malignant melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20140080764A1 true US20140080764A1 (en) | 2014-03-20 |
Family
ID=44393740
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/009,961 Abandoned US20140080764A1 (en) | 2011-04-06 | 2012-04-10 | Drug Containing Recombinant Mistletoe Lectins for Treating Malignant Melanoma |
| US15/064,371 Active US9981007B2 (en) | 2011-04-06 | 2016-03-08 | Drug containing recombinant mistletoe lectins for treating malignant melanoma |
| US15/963,905 Abandoned US20180243366A1 (en) | 2011-04-06 | 2018-04-26 | Drug containing recombinant mistletoe lectins for treating malignant melanoma |
| US17/389,858 Pending US20210379143A1 (en) | 2011-04-06 | 2021-07-30 | Drug containing recombinant mistletoe lectins for treating |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/064,371 Active US9981007B2 (en) | 2011-04-06 | 2016-03-08 | Drug containing recombinant mistletoe lectins for treating malignant melanoma |
| US15/963,905 Abandoned US20180243366A1 (en) | 2011-04-06 | 2018-04-26 | Drug containing recombinant mistletoe lectins for treating malignant melanoma |
| US17/389,858 Pending US20210379143A1 (en) | 2011-04-06 | 2021-07-30 | Drug containing recombinant mistletoe lectins for treating |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20140080764A1 (pl) |
| EP (2) | EP2508195A1 (pl) |
| AU (1) | AU2012238523B2 (pl) |
| CA (1) | CA2832376C (pl) |
| DK (1) | DK2694090T3 (pl) |
| ES (1) | ES2722803T3 (pl) |
| PL (1) | PL2694090T3 (pl) |
| RU (1) | RU2639445C2 (pl) |
| TR (1) | TR201903484T4 (pl) |
| UA (1) | UA115307C2 (pl) |
| WO (1) | WO2012136857A1 (pl) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114126584A (zh) * | 2019-07-09 | 2022-03-01 | 联合化学实验室有限公司 | 重组蛋白质稳定制剂 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3205348A1 (de) * | 2016-02-15 | 2017-08-16 | Melema Pharma GmbH | Arzneimittel enthaltend rekombinante mistellektine zur behandlung von hirntumoren |
| JP2023524151A (ja) | 2020-05-07 | 2023-06-08 | ユニケム ラボラトリーズ リミテッド | 抗癌剤タンパク質 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4221836A1 (de) * | 1992-07-03 | 1994-01-05 | Gabius Hans Joachim Prof Dr | Das biochemisch aufgereinigte Mistel-Lektin (ML-1) als therapeutisch anwendbarer Immunmodulator |
| EP0884388A1 (de) * | 1995-06-26 | 1998-12-16 | MADAUS AG Köln | Transgene Pflanzen enthaltend rekombinantes Mistellektin (rML) |
| DE19752597A1 (de) * | 1997-11-27 | 1999-06-10 | Madaus Ag | Verwendung von Lektinzubereitungen bei der Bekämpfung von Harnblasenkarzinomen |
| DE19804210A1 (de) | 1998-02-03 | 1999-08-12 | Biosyn Arzneimittel Gmbh | Rekombinante Mistellektine |
| ATE362106T1 (de) * | 2001-12-21 | 2007-06-15 | Viscum Ag | Verfahren zur bestimmung der responsivität eines individuums für mistellektin |
-
2011
- 2011-04-06 EP EP11161400A patent/EP2508195A1/de not_active Withdrawn
-
2012
- 2012-04-10 WO PCT/EP2012/056479 patent/WO2012136857A1/de active Application Filing
- 2012-04-10 EP EP12720117.6A patent/EP2694090B1/de active Active
- 2012-04-10 TR TR2019/03484T patent/TR201903484T4/tr unknown
- 2012-04-10 CA CA2832376A patent/CA2832376C/en active Active
- 2012-04-10 US US14/009,961 patent/US20140080764A1/en not_active Abandoned
- 2012-04-10 ES ES12720117T patent/ES2722803T3/es active Active
- 2012-04-10 DK DK12720117.6T patent/DK2694090T3/en active
- 2012-04-10 AU AU2012238523A patent/AU2012238523B2/en active Active
- 2012-04-10 RU RU2013149175A patent/RU2639445C2/ru active
- 2012-04-10 PL PL12720117T patent/PL2694090T3/pl unknown
- 2012-10-04 UA UAA201312897A patent/UA115307C2/uk unknown
-
2016
- 2016-03-08 US US15/064,371 patent/US9981007B2/en active Active
-
2018
- 2018-04-26 US US15/963,905 patent/US20180243366A1/en not_active Abandoned
-
2021
- 2021-07-30 US US17/389,858 patent/US20210379143A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114126584A (zh) * | 2019-07-09 | 2022-03-01 | 联合化学实验室有限公司 | 重组蛋白质稳定制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| PL2694090T3 (pl) | 2019-08-30 |
| US20180243366A1 (en) | 2018-08-30 |
| EP2694090B1 (de) | 2019-01-16 |
| WO2012136857A1 (de) | 2012-10-11 |
| AU2012238523B2 (en) | 2017-05-25 |
| DK2694090T3 (en) | 2019-04-15 |
| EP2508195A1 (de) | 2012-10-10 |
| EP2694090A1 (de) | 2014-02-12 |
| AU2012238523A1 (en) | 2013-10-24 |
| US20210379143A1 (en) | 2021-12-09 |
| RU2013149175A (ru) | 2015-05-20 |
| TR201903484T4 (tr) | 2019-04-22 |
| UA115307C2 (uk) | 2017-10-25 |
| RU2639445C2 (ru) | 2017-12-21 |
| US9981007B2 (en) | 2018-05-29 |
| CA2832376A1 (en) | 2012-10-11 |
| ES2722803T3 (es) | 2019-08-16 |
| CA2832376C (en) | 2020-03-24 |
| US20160175391A1 (en) | 2016-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210379143A1 (en) | Drug containing recombinant mistletoe lectins for treating | |
| CA2138122C (en) | Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma, stomach and breast cancer | |
| ES2317620T3 (es) | Fragmentos de gonadotropina corionica humana (hcg) como inmunorregulador. | |
| TWI593422B (zh) | 新穎之長效升糖素共軛物及包含其用於肥胖預防與治療之醫藥組成物 | |
| EP2684569A1 (en) | A composition for treatment of advanced prostate cancer | |
| EP3065765B1 (en) | Use of il-22 dimers in manufacture of medicaments for treating pancreatitis | |
| US11510966B2 (en) | Use of IL-22 in treating necrotizing enterocolitis | |
| TWI657821B (zh) | 用於治療ｃ－ｍｅｔ相關性癌症的方法和組成物 | |
| US20100330093A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| JPH03503647A (ja) | 黒色腫の治療のためのｉｌ‐２とｄｔｉｃとの組合せ療法 | |
| US20100197595A1 (en) | Treatment of melanoma with alpha thymosin peptides | |
| US20220249425A1 (en) | Methods for treating breast cancer | |
| US20210154265A1 (en) | Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment | |
| EP4180055A1 (en) | Use of mitoxantrone hydrochloride liposome and pegaspargase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: CYTAVIS BIOPHARMA GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LENTZEN, HANS;WITTHORN, KLAUS;REEL/FRAME:031530/0047 Effective date: 20131016 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |